Can-Fite BioPharma Ltd. reports developments for a clinical-stage biotechnology pipeline of proprietary small-molecule drugs targeting the A3 adenosine receptor (A3AR). Recurring news covers Namodenoson and Piclidenoson across oncology, inflammatory disease, liver disorders, metabolic disease, obesity-related uses, and companion-animal osteoarthritis through its veterinary commercialization relationship.
Company updates also include clinical and regulatory disclosures, patent allowances in multiple jurisdictions, operating and financial results, material agreements, capital-structure actions, and governance matters tied to its American Depositary Shares and ordinary-share voting processes.
Can-Fite BioPharma (CANF) announced that the first 247 patients completed dosing in its pivotal Phase III Piclidenoson trial for moderate-to-severe plaque psoriasis. The company expects the independent data monitoring committee to report interim efficacy and safety results in Q1 2027.
The randomized, double-blind trial is being run under a protocol agreed with the FDA and EMA. Patients take either 3 mg of Piclidenoson or a placebo by mouth twice daily. The trial has two primary measures of effectiveness at Week 16: the share of patients with at least a 75% improvement on the Psoriasis Area and Severity Index and the share with a physician assessment score of 0 or 1, meaning clear or almost clear skin. The Piclidenoson development program includes safety data from more than 1,500 subjects.
Can-Fite BioPharma (CANF) announced published preclinical findings showing piclidenoson improved kidney protein reabsorption in experimental models of Lowe syndrome. The research appeared in Signal Transduction and Targeted Therapy, a Nature Portfolio journal. Activity was demonstrated in patient-derived kidney cells, human kidney organoids and a humanized mouse model. After five months, treated mice had 48–80% lower urinary levels of a protein-loss marker than untreated disease-model mice.
A proposed Phase II study is under review by Italian Health Authorities. The open-label, single-center trial would evaluate twice-daily oral treatment for six months in 5 adults with genetically confirmed Lowe syndrome. Its primary endpoint measures improvement in kidney uptake of 99mTc-DMSA to assess protein reabsorption capacity.
Can-Fite BioPharma (CANF) reported ten-year overall survival for a patient with advanced liver cancer from its completed Phase II Namodenoson study. The patient, whose complete response was previously reported, remains cancer-free and in good health.
Namodenoson is being evaluated in an ongoing randomized, double-blind, placebo-controlled pivotal Phase III study in advanced hepatocellular carcinoma and underlying Child-Pugh B7 cirrhosis. Can-Fite said longer-than-anticipated survival across the pooled, blinded population prompted evaluation of earlier timing for the planned interim analysis. That observation includes both treatment and placebo patients; treatment-specific efficacy awaits the planned analysis.
Can-Fite BioPharma (CANF) plans to pursue licensing and development partnerships at BIO-Europe in Cologne, Germany, on November 9–11, 2026. Digital partnering sessions follow November 17–18. Existing regional licensing agreements have generated approximately $20 million in upfront and milestone payments to date, with potential additional milestones and royalties.
The company described final Phase IIa pancreatic cancer results for namodenoson as showing favorable safety and encouraging exploratory survival findings. Its pivotal Phase III liver cancer study remains ongoing, with longer-than-anticipated blinded overall survival and an interim analysis planned. Piclidenoson's pivotal Phase III psoriasis program has reached its prespecified interim analysis stage; results are expected in Q1 2027. Other programs include Phase IIb development in MASH and a Telethon-backed Lowe syndrome collaboration, supported by a Eurasian patent allowance covering Lowe syndrome and Dent disease 2.
Can-Fite BioPharma (CANF) announced Eurasian patent allowance for Piclidenoson use in diseases associated with OCRL deficiency, including Lowe syndrome.
The Eurasian Patent Office issued a notification of readiness to grant; claims also cover Dent disease 2. Fondazione Telethon owns the application, and the grant remains subject to required formalities. Can-Fite holds development, commercialization, and out-licensing rights for Lowe syndrome under its agreement with Telethon.
The partners have signed a clinical development collaboration. A Phase 2 open-label, single-center study is designed to assess oral Piclidenoson in 5 adults with genetically confirmed Lowe syndrome. Its primary endpoint measures improvement in renal uptake of a tracer to assess kidney tubular reabsorption capacity.
Can-Fite BioPharma (CANF) presented final Phase IIa pancreatic cancer data at ESMO 2026, with namodenoson meeting its primary safety endpoint. The single-center, open-label study enrolled 20 previously treated patients receiving 25 mg twice daily: 14 third-line, three second-line and three fourth-line patients.
Five related or possibly related adverse events in three patients were mild to moderate; none required treatment changes. No Grade ≥3 treatment-related or treatment-related serious adverse events occurred. A post hoc analysis of eight third-line patients surviving beyond two months found median overall survival of 6.28 months and median progression-free survival of 2.27 months. One second-line patient had progression-free survival of 16.39 months. The survival-selected subgroup and lack of a randomized comparator make the exploratory findings hypothesis-generating, supporting evaluation in a larger randomized study.
Can-Fite BioPharma (CANF) reported a peer-reviewed case study of a patient with advanced decompensated liver cirrhosis treated with its investigational drug Namodenoson. During treatment, the patient’s ascites resolved, diuretic therapy was discontinued, and follow-up endoscopy showed only minimal residual esophageal varices, while hepatic synthetic function continued to deteriorate. The patient remained clinically stable for approximately 28 months on Namodenoson and subsequently underwent successful orthotopic liver transplantation from a deceased donor in January 2026, with favorable post-transplant recovery. The report appears in the Japanese Journal of Gastroenterology and Hepatology.
Can-Fite BioPharma (CANF) reported H1 2026 results with a $4.6 million net loss and highlighted late-stage clinical progress.
Revenues were stable at $0.20 million versus H1 2025, while research and development expenses rose 13.86% to $3.45 million, mainly due to Namodenoson and Piclidenoson trials. General and administrative expenses decreased 31.40% to $1.42 million, narrowing the net loss from $4.87 million to $4.60 million. Cash, cash equivalents and short-term deposits stood at $7.03 million on June 30, 2026, before approximately $4.0 million gross proceeds from September warrant exercises.
Clinically, a Phase IIa pancreatic cancer study of Namodenoson met its primary safety endpoint and showed durable overall survival in heavily pretreated patients. In the pivotal Phase III HCC trial, blinded overall survival appears longer than study design assumptions, prompting evaluation of an earlier interim analysis. Piclidenoson’s pivotal psoriasis Phase 3 reached its pre-specified interim analysis, with results expected in Q1 2027, and new patents expanded protection for both drugs in multiple countries.
Can-Fite BioPharma (CANF) entered a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 1,591,738 ADSs at a reduced exercise price of $2.50 per ADS, down from $5.00. Gross proceeds are expected to be approximately $4.0 million before fees and expenses.
In consideration for the cash exercise, Can-Fite will issue new unregistered warrants to purchase up to 3,183,476 ADSs, also at $2.50 per ADS, exercisable until 24 months after the effective date of a planned resale registration statement. Closing of the offering is expected on or about September 3, 2026, with H.C. Wainwright & Co. as exclusive placement agent. The company intends to use net proceeds for research and development, clinical trials, and general corporate and working capital purposes.
Can-Fite BioPharma (CANF) reported that blinded overall survival in its ongoing pivotal Phase III Namodenoson study in advanced hepatocellular carcinoma appears longer than originally anticipated based on the study’s design assumptions.
The randomized, double-blind, placebo-controlled trial enrolls patients with advanced HCC and Child-Pugh B7 cirrhosis, allocating them 2:1 to Namodenoson or placebo, with overall survival as the primary endpoint. The observed survival data are pooled and blinded, covering both treatment and placebo arms, so no conclusions about Namodenoson’s efficacy or differences between groups can currently be drawn. In response to the longer-than-expected survival, Can-Fite is evaluating advancing the timing of the trial’s planned interim analysis, which will allow an independent assessment of overall survival between the two arms under the statistical analysis plan and relevant regulatory requirements. The company’s CEO and CFO stated that, while the study remains blinded, an earlier interim look may offer important information on Namodenoson’s potential clinical benefit in this high unmet-need population.